Meta-Analysis of Complete Remission Rates Following First-Line Salvage Treatment after Anti-CD19 CAR-T Failure in Adult Patients with Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia

被引：0
|
作者：
Tomasik, Jaromir [1 ]
Bilicki, Dominik [1 ]
Basak, Grzegorz [1 ]
机构：
[1] Med Univ Warsaw, Dept Hematol Transplantat & Internal Med, Warsaw, Poland
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-204502
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1421 / 1422
页数：2
相关论文
共 50 条
  • [21] Analysis Benefits of a Second Allo-HSCT after CAR-T Cell Therapy in 97 Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Who Relapsed after a First Transplant
    Cao, Xing-yu
    Zhang, Jian-Ping
    Zhao, Yan-Li
    Xiong, Min
    Zhou, Jiarui
    Lu, Yue
    Sun, Ruijuan
    Wei, Zhijie
    Liu, Deyan
    Zhang, Xian
    Yang, Junfang
    Lu, Peihua
    BLOOD, 2022, 140 : 4802 - 4803
  • [22] Impact of pre-infusion disease burden on outcomes in pediatric relapsed/refractory B-cell lymphoblastic leukemia following anti-CD19 CAR T-cell therapy
    Shang, Qianwen
    Wang, Yu
    Lu, Aidong
    Jia, Yueping
    Zuo, Yingxi
    Zeng, Huimin
    Zhang, Leping
    LEUKEMIA & LYMPHOMA, 2025, 66 (01) : 54 - 63
  • [23] Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant
    Cao, Xing-yu
    Zhang, Jian-ping
    Zhao, Yan-li
    Xiong, Min
    Zhou, Jia-rui
    Lu, Yue
    Sun, Rui-juan
    Wei, Zhi-jie
    Liu, De-yan
    Zhang, Xian
    Yang, Jun-fang
    Lu, Peihua
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [24] Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation
    Liu, Shuangyou
    Deng, Biping
    Yin, Zhichao
    Lin, Yuehui
    An, Lihong
    Liu, Dan
    Pan, Jing
    Yu, Xinjian
    Chen, Bingzhen
    Wu, Tong
    Chang, Alex H.
    Tong, Chunrong
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (06) : 671 - 679
  • [25] Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product in a First-in-Human Trial (PALL) in Pediatric Patients with CD19+Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
    Qasim, Waseem
    Ciocarlie, Oana
    Adams, Stuart
    Inglott, Sarah
    Murphy, Claire
    Rivat, Christine
    Wright, Gary
    Lucchini, Giovanna
    Silva, Juliana
    Rao, Kanchan
    Zinai, Amina
    Binlich, Florence
    Dupouy, Sandra
    Pauly, Jeanne
    Balandraud, Svetlana
    Dubois, Frederic
    Konto, Cyril
    Patel, Premal
    Chiesa, Robert
    Samarasinghe, Sujith
    Hara, Havinder
    Boyle, Alayna
    Chu, Jan
    Pinner, Danielle
    Amrolia, Persis J.
    Vora, Ajay
    Rao, Anupama
    Ancliffe, Philip
    Veys, Paul
    BLOOD, 2017, 130
  • [26] Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study
    Junfang Yang
    Jiaping He
    Xian Zhang
    Jingjing Li
    Zhenguang Wang
    Yongliang Zhang
    Liyuan Qiu
    Qionglu Wu
    Zhe Sun
    Xun Ye
    Wenjie Yin
    Wei Cao
    Lianjun Shen
    Martina Sersch
    Peihua Lu
    Blood Cancer Journal, 12
  • [27] Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study
    Yang, Junfang
    He, Jiaping
    Zhang, Xian
    Li, Jingjing
    Wang, Zhenguang
    Zhang, Yongliang
    Qiu, Liyuan
    Wu, Qionglu
    Sun, Zhe
    Ye, Xun
    Yin, Wenjie
    Cao, Wei
    Shen, Lianjun
    Sersch, Martina
    Lu, Peihua
    BLOOD CANCER JOURNAL, 2022, 12 (07)
  • [28] Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia
    Zhou, Qianyi
    An, Yuxin
    Zhang, Xiaomei
    Xiao, Xia
    Bai, Xue
    Liu, Pengjiang
    Pu, Yedi
    Meng, Juanxia
    Zhu, Haibo
    Lyu, Cuicui
    Zhang, Huan
    Zhang, Yu
    Xie, Tianle
    Meng, Haotian
    Lyu, Hairong
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [29] Safe and potent anti-CD19 CAR T-cells with shRNA-IL-6 gene silencing element in patients with refractory or relapsed B-cell acute lymphoblastic leukemia
    Ma, Jin-Feng
    Yan, Jia-Wei
    Liu, Mei-Jing
    Yan, Chun-Long
    Tang, Xiao-Wen
    Qiu, Hui-Ying
    Miao, Miao
    Han, Yue
    Li, Li-Min
    Kang, Li-Qing
    Xu, Nan
    Yu, Zhou
    Tan, Jing-Wen
    Zhu, Hong-Jia
    Jia, Xu
    Zhang, Zhi-Zhi
    Wang, Miao
    Dai, Hai-Ping
    Yu, Lei
    Xue, Sheng-Li
    Wu, De-Pei
    Gong, Wen-Jie
    HEMASPHERE, 2024, 8 (10):
  • [30] CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
    Baird, John H.
    Frank, Matthew J.
    Craig, Juliana
    Patel, Shabnum
    Spiegel, Jay Y.
    Sahaf, Bita
    Younes, Sheren F.
    Oak, Jean S.
    Natkunam, Yasodha
    Ehlinger, Zachary
    Reynolds, Warren D.
    Arai, Sally
    Johnston, Laura J.
    Lowsky, Robert
    Negrin, Robert S.
    Rezvani, Andrew R.
    Shiraz, Parveen
    Sidana, Surbhi
    Weng, Wen-Kai
    Schultz, Liora M.
    Ramakrishna, Sneha
    Davis, Kara L.
    Feldman, Steven A.
    Mackall, Crystal L.
    Miklos, David B.
    Muffly, Lori S.
    BLOOD, 2020, 136
12345